



Abstract Session #1, N-225

Hepatic Physiology and Metabolism & Liver Injury		
1	14:15	Angiotensin-like 4 is Involved in Glucocorticoid-induced Hepatic Ceramide Production that Leads to Insulin Resistance and Dyslipidemia <i>Tzu-Chieh Chen, Daniel I. Benjamin, Taiyi Kuo, Nora E. Gray, Daniel K. Nomura, Jen-Chywan Wang</i>
2	14:30	The Role of Organic Cation Transporter 1 (OCT1; SLC22A1) in Modulating Hepatic Glucose Metabolism <i>Xiaomin Liang, Qi Luo, Meiling Piao, Eugene C. Chen, Huan-Chieh Chien, Kathleen M. Giacomini</i>
3	14:45	Regulation of hepatic lipid metabolism by hypothalamic Agouti-related Protein <i>Matthew Todd Maier, Eirini Vagena, Anna Vilhelmsson, Sharon Louie, Daniel Nomura, Suneil Koliwad, Allison W. Xu</i>
4	15:00	Real-time comparison of the hepatic metabolism of fructose and glucose in vivo using hyperpolarized [2-¹³C]dihydroxyacetone <i>Irene Marco-Rius, Cornelius von Morze, Renuka Sriram, Peng Cao, Gene-Yuan Chang, Michael A Ohliger, David Pearce, John Kurhanewicz, Peder EZ Larson, Matthew Merritt, Daniel B Vigneron</i>
	15:15	Break
5	15:30	CMV infection leads to heterologous adaptive and innate immunity against chronic RNA viruses---implications for the design of CMV-vectored HCV and HIV-1 vaccines <i>James C. Ryan, Erene C, Niemi, Jennifer Evans, Lia Avanesyan, Stewart Cooper, Kim Page</i>
6	15:45	Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Predict Drug-Induced Liver Injury (DILI) Risk <i>Rosa Chan, Leslie Z. Benet</i>
7	16:00	Xenon or isoflurane preconditioning decrease liver ischemia reperfusion injury <i>Garrett R Roll, Ting Yang, Lee P Lim, Holger Willenbring, John P Roberts, Claus U Niemann</i>
8	16:15	OCT1 is a Novel Transporter of Paraquat and Enhances its Cytotoxicity <i>Meiling Piao, Xiaomin Liang, Sook Wah Yee, Qi Luo, Kathleen M. Giacomini</i>



Abstract Session #2, N-217

Progenitor Cells, Growth and Development		
9	14:15	A genetically engineered mouse model of fibrolamellar hepatocellular carcinoma <i>Garry Coles, Lei Xu, Thuyen Nguyen, Julien Sage</i>
10	14:30	TSPY is a novel biomarker for a subclass of male HCC with global DNA hypomethylation. <i>Tatsuo Kido, Yun-Fai Chris Lau</i>
11	14:45	Precision Therapeutics of Cholangiocarcinoma using a Novel Patient-derived Model of Drug Resistance <i>Kan Toriguchi, David Donner, Eric Nakakura, Carlos Corvera, Michele Lin, Byron Hann, Robert S. Warren</i>
12	15:00	mTOR inhibitor for the treatment of AKT/Yap driven cholangiocarcinoma in mice <i>Shanshan Zhang, Dan Cao, Biao Fan, Xinhua Song, Xin Chen</i>
	15:15	Break
13	15:30	Modeling Cystic Fibrosis Liver Disease Using Induced Pluripotent Stem Cell Derived Cholangiocytes <i>Daniela Castano, Cristina Esteva-Font, Aras N Mattis</i>
14	15:45	Bioengineered AAV capsids with enhanced human hepatocyte transduction and unique humoral neutralization profiles for use in gene delivery and genome editing approaches in human liver. <i>Nicole K. Paulk, Allison Dane, Sean Nygaard, Katja Pekrun, Leszek Lisowski, Kirk Chu, Yue Zhang, Annelise Haft, Marc Valentine, Andrew Davidoff, Amit Nathwani, Markus Grompe, Mark A. Kay</i>
15	16:00	Self-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver <i>Bruce Wang, Roel Nusse</i>